Galectin Therapeutics Inc. (GALT)

Over the past six months, Galectin Therapeutics' stock price has been impacted by several events. In December 2025, the stock plummeted after the company received written feedback from the FDA regarding its belapectin development program, leading to a follow-up Type C meeting, however, the company announced a new $10 million unsecured, convertible line of credit from its chairman. In March 2026, the company reported its 2025 financial results and provided a business update, highlighting progress on belapectin for MASH cirrhosis and portal hypertension, noting a decrease in R&D expenses and an improved net loss. In February 2026, Galectin Therapeutics hosted a virtual Key Opinion Leader (KOL) event to discuss the belapectin development program for MASH cirrhosis and portal hypertension. In November 2025, the company reported financial results for the quarter ended September 30, 2025, and provided a business update on belapectin from the NAVIGATE trial.

There is no specific information available regarding demand seasonality for Galectin Therapeutics, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its primary focus is on drug development and clinical trials, so traditional demand seasonality does not typically apply to its current operations. The demand for its lead product candidate, belapectin, would be driven by the progression of its clinical trials and eventual regulatory approval.

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases and cancer, operating within the Healthcare sector and Biotechnology industry. Their primary product candidate, belapectin (GR-MD-02), a galectin-3 inhibitor, is in Phase 2 clinical studies for MASH patients with advanced fibrosis and compensated cirrhosis with portal hypertension. Preclinical models suggest belapectin can reverse liver fibrosis and cirrhosis, and it is also being explored for oncology indications and severe skin disease. The company has a joint venture with SBH Sciences, Inc. to develop small organic molecule inhibitors of galectin-3 for oral administration.

Galectin Therapeutics, Inc. is headquartered in Norcross, Georgia, a suburb of Atlanta. The company also maintains a laboratory-based effort in the Boston area at SBH Sciences in Natick, MA.

Information directly detailing Galectin Therapeutics, Inc.'s "brand reputation" in the past year is not explicitly available in the search results. However, the FDA feedback in December 2025, which led to a stock price drop, may have negatively impacted investor confidence. Positive clinical trial signals and financial updates in March 2026 likely contributed positively to the company's reputation. The appointment of Henry Brem, M.D., as a board member in March 2026 may have enhanced the company's perceived leadership and strategic direction.

The ownership structure of Galectin Therapeutics (GALT) stock includes institutional, insider, and retail investors. As of May 5, 2026, there are 98 institutional owners and shareholders holding a total of 11,417,290 shares, with major holders including Vanguard Group Inc and BlackRock, Inc. Insiders own approximately 27.64% of the company's stock, with Richard E. Uihlein being the largest individual shareholder. The general public, including retail investors, owns a significant portion, around 54% to 63.06% of the company.